KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Beginning Cash Balance: 2011-2024

Historic Beginning Cash Balance for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to $82.2 million.

  • Esperion Therapeutics' Beginning Cash Balance fell 54.54% to $86.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.7 million, marking a year-over-year increase of 26.02%. This contributed to the annual value of $82.2 million for FY2024, which is 34.08% down from last year.
  • As of FY2024, Esperion Therapeutics' Beginning Cash Balance stood at $82.2 million, which was down 34.08% from $124.8 million recorded in FY2023.
  • Esperion Therapeutics' 5-year Beginning Cash Balance high stood at $258.9 million for FY2022, and its period low was $82.2 million during FY2024.
  • Moreover, its 3-year median value for Beginning Cash Balance was $124.8 million (2023), whereas its average is $155.3 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Beginning Cash Balance spiked by 363.47% in 2020, and later tumbled by 51.80% in 2023.
  • Esperion Therapeutics' Beginning Cash Balance (Yearly) stood at $167.1 million in 2020, then surged by 52.62% to $255.0 million in 2021, then grew by 1.54% to $258.9 million in 2022, then plummeted by 51.80% to $124.8 million in 2023, then plummeted by 34.08% to $82.2 million in 2024.